Skip to content
RNAWiki
Checking…
All public datasets

Public dataset

Recorded enzyme and transporter findings by polarity

Inspect every admitted source sentence for an exact medicine, enzyme or transporter, and recorded role, with assertions, denials, and unresolved polarity counted separately.

What this does not mean: This is not a drug interaction checker. A denial applies only to the named medicine, role, counterparty, conditions, and source sentence; it is not proof of no interaction and is not dosing or treatment advice.
Public rows
8,404
Generated
Schema version
1.3.0

Coverage

What this run contains

Medicine–counterparty–role groups
8,404
Source sentence records
20,358
Asserted sentences
4,700
Denied sentences
7,494
Polarity not recorded
8,164
Medicines represented
755
Counterparties represented
36
Corpus records considered
9,855
All corpus records were checked; a record without a documented counterparty cannot produce a row in this projection.
inducer groups
617
inhibitor groups
3,131
not_recorded groups
3,074
substrate groups
1,582

Method

How the rows were made

  1. A deterministic parser reads recorded FDA-label excerpts for named enzymes and transporters.
  2. A mention is admitted only when the stored excerpt contains the recorded counterparty, allowing letter-case differences only.
  3. Every admitted mention is grouped by exact medicine slug, recorded counterparty spelling, and exact role. A missing role remains NOT_RECORDED rather than being assigned to another group.
  4. Each sentence carries the exact source version and effective date when recorded; the API serializes null and the page says not recorded when either is absent.
  5. The API paginates groups. Within each returned group, sentences is the complete untruncated list used by the three polarity counts.

Limits

Read these before using a row

  • A recorded role is a mechanistic statement copied from a descriptive label section. It is not a clinical interaction, and nothing in this dataset describes what happens when a person is exposed to two medicines at once.
  • This dataset holds no relation between one medicine and another. Counts are per counterparty; the medicines naming a counterparty are listed with their sentences and are never paired, ranked against each other or compared.
  • ICH M12 states that no potency classification system exists for transporters or for non-CYP enzymes, so no strong, moderate or weak vocabulary is applied to any counterparty here. The tallies count records, not strength.
  • A counterparty with a high count is one that labels document often. Documentation frequency is not importance: US labelling asks for some enzymes to be characterised far more routinely than others, and that requirement is part of what these counts measure.
  • 40.1% of admitted mentions carry no role. The sentence named more than one role and the parser left the question open rather than attaching a guess, so a role tally is a count of sentences that settled the question, not of medicines for which it is settled.
  • Recorded spellings are counted separately and never merged. P-GP, PGP and P-GLYCOPROTEIN are three entries in this dataset because they are three strings in the corpus; whether they name one thing is a question for a person, and prefix relationships are reported as questions rather than resolved.
  • 9088 of 9855 records name no enzyme or transporter at all. That is an absence of recorded text in the sources fetched for those records. It is neither reassurance nor alarm about the medicines concerned.
  • 20358 of 20358 admitted mentions come from records the deterministic label parser produced, where no person chose the value or wrote its measurement context. The sentence is stored with each one so a reader can check it.
  • The uniform reference for concentration allocates the same 20358 mentions over the same 36 counterparties by chance. Labels are not written that way, so the reference shows only that the observed spread is not a consequence of how many mentions there are.
  • The public rows enumerate documentation about one medicine and one named counterparty. They never create medicine-to-medicine pairs and cannot answer whether two medicines interact.
  • A NOT_RECORDED role or polarity remains unresolved. It is never folded into an assertion or a denial.
  • Each returned group includes every admitted source sentence for checking, but the full source document remains authoritative.

Provenance

Source examples

Abacavir · CYP3A4 inhibitor

2 asserted · 2 denied · 0 polarity not recorded

FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)
In vitro experiments reveal that abacavir does not inhibit human CYP3A4, CYP2D6, or CYP2C9 activity at clinically relevant concentrations.

Abacavir · BCRP substrate

0 asserted · 4 denied · 0 polarity not recorded

FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)
Based on in vitro study results, abacavir at therapeutic drug exposures is not expected to affect the pharmacokinetics of drugs that are substrates of the following transporters: organic anion transporter polypeptide (OATP)1B1/3, breast cancer resistance protein (BCRP) or P-glycoprotein (P-gp), organic cation transporter (OCT)1, OCT2, or multidrug and toxic extrusion protein (MATE)1 and MATE2-K.

Abacavir · CYP2C9 not_recorded

0 asserted · 0 denied · 2 polarity not recorded

FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)
Abacavir did not inhibit or induce other CYP enzymes (such as CYP2C9, or CYP2D6).

Artifact used for this view: data/agents/current/enzyme-and-transporter-documentation.json. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.

Schema

Fields in the public projection

FieldTypeMeaning
medicineSlugstringStable RNAWiki medicine route key.
medicineNamestringRecorded medicine name; not normalized for display style.
counterpartystringThe exact recorded counterparty spelling.
rolestringSUBSTRATE, INHIBITOR, INDUCER, or NOT_RECORDED when the sentence did not settle one role.
assertedCountnumberSentence records whose polarity is ASSERTED.
deniedCountnumberSentence records whose polarity is NEGATED.
polarityNotRecordedCountnumberSentence records for which the parser did not settle assertion or denial.
sentencessentence[]Every admitted sentence for this group, with polarity, section, source identity, source version/effective date or explicit absence, retrieval date, and exact excerpt. The list is not truncated.

Reader

Search and filter the rows

Case-insensitive text search over the public fields named for this dataset.

Exact recorded role.

Exact recorded counterparty spelling.

Clear

Showing 931–940 of 8,404 matching rows. Filters and search terms remain attached when you move between pages or open the API view.

  1. Projected row 931

    Medicine slug
    brensocatib
    Medicine name
    Brensocatib
    Enzyme or transporter
    P-GP
    Role
    INHIBITOR
    Asserted sentences
    4
    Denied sentences
    0
    Polarity not recorded
    0
    Complete sentence records
    1. ASSERTEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:b56986ae-e7db-421e-b622-a7f41e321f3d (opens source in a new tab)

      Brensocatib label

      Version not recorded · Effective date not recorded

      Drug Interaction Studies Clinical Studies and Model-Informed Approaches Strong CYP3A4 and P-gp Inhibitors : Brensocatib C max increased by 68% and AUC increased by 55% following concomitant administration with clarithromycin (a strong CYP3A4 and P-gp inhibitor) 500 mg twice daily for 6 days.
    2. ASSERTEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:b56986ae-e7db-421e-b622-a7f41e321f3d (opens source in a new tab)

      Brensocatib label

      Version not recorded · Effective date not recorded

      Moderate CYP3A4 and P-gp Inhibitors : Brensocatib C max increased by 53% and AUC increased by 32% following concomitant administration with verapamil (a moderate CYP3A4 and P-gp inhibitor) 240 mg once daily for 5 days.
    3. ASSERTEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:b56986ae-e7db-421e-b622-a7f41e321f3d (opens source in a new tab)

      Brensocatib label

      Version not recorded · Effective date not recorded

      Drug Interaction Studies Clinical Studies and Model-Informed Approaches Strong CYP3A4 and P-gp Inhibitors : Brensocatib C max increased by 68% and AUC increased by 55% following concomitant administration with clarithromycin (a strong CYP3A4 and P-gp inhibitor) 500 mg twice daily for 6 days.
    4. ASSERTEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:b56986ae-e7db-421e-b622-a7f41e321f3d (opens source in a new tab)

      Brensocatib label

      Version not recorded · Effective date not recorded

      Moderate CYP3A4 and P-gp Inhibitors : Brensocatib C max increased by 53% and AUC increased by 32% following concomitant administration with verapamil (a moderate CYP3A4 and P-gp inhibitor) 240 mg once daily for 5 days.

  2. Projected row 932

    Medicine slug
    brensocatib
    Medicine name
    Brensocatib
    Enzyme or transporter
    P-GP
    Role
    NOT_RECORDED
    Asserted sentences
    0
    Denied sentences
    0
    Polarity not recorded
    4
    Complete sentence records
    1. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:b56986ae-e7db-421e-b622-a7f41e321f3d (opens source in a new tab)

      Brensocatib label

      Version not recorded · Effective date not recorded

      Transporter Systems : Brensocatib is a substrate of P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP), but is not a substrate of MATE1, MATE2-K, OAT1, OAT3, OATP1B1, OATP1B3, OCT1, and OCT2.
    2. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:b56986ae-e7db-421e-b622-a7f41e321f3d (opens source in a new tab)

      Brensocatib label

      Version not recorded · Effective date not recorded

      Brensocatib is an inhibitor of BCRP, OATP1B, MATE1, and MATE2-K, but is not an inhibitor of P-gp, OAT1, OCT2, OAT3, or OATP1B3.
    3. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:b56986ae-e7db-421e-b622-a7f41e321f3d (opens source in a new tab)

      Brensocatib label

      Version not recorded · Effective date not recorded

      Transporter Systems : Brensocatib is a substrate of P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP), but is not a substrate of MATE1, MATE2-K, OAT1, OAT3, OATP1B1, OATP1B3, OCT1, and OCT2.
    4. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:b56986ae-e7db-421e-b622-a7f41e321f3d (opens source in a new tab)

      Brensocatib label

      Version not recorded · Effective date not recorded

      Brensocatib is an inhibitor of BCRP, OATP1B, MATE1, and MATE2-K, but is not an inhibitor of P-gp, OAT1, OCT2, OAT3, or OATP1B3.

  3. Projected row 933

    Medicine slug
    brentuximab-vedotin
    Medicine name
    Brentuximab Vedotin
    Enzyme or transporter
    CYP3A4
    Role
    INDUCER
    Asserted sentences
    2
    Denied sentences
    0
    Polarity not recorded
    0
    Complete sentence records
    1. ASSERTEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:3904f8dd-1aef-3490-e48f-bd55f32ed67f (opens source in a new tab)

      Brentuximab Vedotin label

      Version not recorded · Effective date not recorded

      Co-administration of ADCETRIS with rifampin, a potent CYP3A4 inducer, reduced exposure to MMAE by approximately 46%.
    2. ASSERTEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:3904f8dd-1aef-3490-e48f-bd55f32ed67f (opens source in a new tab)

      Brentuximab Vedotin label

      Version not recorded · Effective date not recorded

      Co-administration of ADCETRIS with rifampin, a potent CYP3A4 inducer, reduced exposure to MMAE by approximately 46%.

  4. Projected row 934

    Medicine slug
    brentuximab-vedotin
    Medicine name
    Brentuximab Vedotin
    Enzyme or transporter
    CYP3A4
    Role
    INHIBITOR
    Asserted sentences
    2
    Denied sentences
    2
    Polarity not recorded
    0
    Complete sentence records
    1. ASSERTEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:3904f8dd-1aef-3490-e48f-bd55f32ed67f (opens source in a new tab)

      Brentuximab Vedotin label

      Version not recorded · Effective date not recorded

      Drug Interaction Studies Effects of Other Drugs on ADCETRIS Co-administration of ADCETRIS with ketoconazole, a potent CYP3A4 inhibitor, increased exposure to MMAE by approximately 34%.
    2. ASSERTEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:3904f8dd-1aef-3490-e48f-bd55f32ed67f (opens source in a new tab)

      Brentuximab Vedotin label

      Version not recorded · Effective date not recorded

      Drug Interaction Studies Effects of Other Drugs on ADCETRIS Co-administration of ADCETRIS with ketoconazole, a potent CYP3A4 inhibitor, increased exposure to MMAE by approximately 34%.
    3. NEGATEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:3904f8dd-1aef-3490-e48f-bd55f32ed67f (opens source in a new tab)

      Brentuximab Vedotin label

      Version not recorded · Effective date not recorded

      In vitro studies using human liver microsomes indicate that MMAE inhibits CYP3A4/5 but not other CYP450 isoforms.
    4. NEGATEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:3904f8dd-1aef-3490-e48f-bd55f32ed67f (opens source in a new tab)

      Brentuximab Vedotin label

      Version not recorded · Effective date not recorded

      In vitro studies using human liver microsomes indicate that MMAE inhibits CYP3A4/5 but not other CYP450 isoforms.

  5. Projected row 935

    Medicine slug
    brentuximab-vedotin
    Medicine name
    Brentuximab Vedotin
    Enzyme or transporter
    CYP3A4
    Role
    NOT_RECORDED
    Asserted sentences
    0
    Denied sentences
    0
    Polarity not recorded
    2
    Complete sentence records
    1. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:3904f8dd-1aef-3490-e48f-bd55f32ed67f (opens source in a new tab)

      Brentuximab Vedotin label

      Version not recorded · Effective date not recorded

      In vitro data indicate that the MMAE metabolism that occurs is primarily via oxidation by CYP3A4/5.
    2. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:3904f8dd-1aef-3490-e48f-bd55f32ed67f (opens source in a new tab)

      Brentuximab Vedotin label

      Version not recorded · Effective date not recorded

      In vitro data indicate that the MMAE metabolism that occurs is primarily via oxidation by CYP3A4/5.

  6. Projected row 936

    Medicine slug
    brentuximab-vedotin
    Medicine name
    Brentuximab Vedotin
    Enzyme or transporter
    CYP3A4
    Role
    SUBSTRATE
    Asserted sentences
    0
    Denied sentences
    2
    Polarity not recorded
    0
    Complete sentence records
    1. NEGATEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:3904f8dd-1aef-3490-e48f-bd55f32ed67f (opens source in a new tab)

      Brentuximab Vedotin label

      Version not recorded · Effective date not recorded

      Effects of ADCETRIS on Other Drugs Co-administration of ADCETRIS did not affect exposure to midazolam, a CYP3A4 substrate.
    2. NEGATEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:3904f8dd-1aef-3490-e48f-bd55f32ed67f (opens source in a new tab)

      Brentuximab Vedotin label

      Version not recorded · Effective date not recorded

      Effects of ADCETRIS on Other Drugs Co-administration of ADCETRIS did not affect exposure to midazolam, a CYP3A4 substrate.

  7. Projected row 937

    Medicine slug
    brentuximab-vedotin
    Medicine name
    Brentuximab Vedotin
    Enzyme or transporter
    P-GP
    Role
    NOT_RECORDED
    Asserted sentences
    0
    Denied sentences
    0
    Polarity not recorded
    2
    Complete sentence records
    1. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:3904f8dd-1aef-3490-e48f-bd55f32ed67f (opens source in a new tab)

      Brentuximab Vedotin label

      Version not recorded · Effective date not recorded

      In vitro studies indicate that MMAE is a substrate and not an inhibitor of the efflux transporter P‑glycoprotein (P-gp).
    2. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:3904f8dd-1aef-3490-e48f-bd55f32ed67f (opens source in a new tab)

      Brentuximab Vedotin label

      Version not recorded · Effective date not recorded

      In vitro studies indicate that MMAE is a substrate and not an inhibitor of the efflux transporter P‑glycoprotein (P-gp). 12.6 Immunogenicity The observed incidence of anti-drug antibodies is highly dependent on the sensitivity and specificity of the assay.

  8. Projected row 938

    Medicine slug
    brexpiprazole
    Medicine name
    Brexpiprazole
    Enzyme or transporter
    BCRP
    Role
    SUBSTRATE
    Asserted sentences
    0
    Denied sentences
    2
    Polarity not recorded
    0
    Complete sentence records
    1. NEGATEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:993b584c-7fe6-4551-899f-39146c8508ac (opens source in a new tab)

      Brexpiprazole label

      Version not recorded · Effective date not recorded

      In vitro studies of brexpiprazole did not indicate that brexpiprazole is a substrate of efflux transporters such as MDRI (P-gp) and BCRP.
    2. NEGATEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:993b584c-7fe6-4551-899f-39146c8508ac (opens source in a new tab)

      Brexpiprazole label

      Version not recorded · Effective date not recorded

      In vitro studies of brexpiprazole did not indicate that brexpiprazole is a substrate of efflux transporters such as MDRI (P-gp) and BCRP.

  9. Projected row 939

    Medicine slug
    brexpiprazole
    Medicine name
    Brexpiprazole
    Enzyme or transporter
    CYP1A1
    Role
    NOT_RECORDED
    Asserted sentences
    0
    Denied sentences
    0
    Polarity not recorded
    2
    Complete sentence records
    1. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:993b584c-7fe6-4551-899f-39146c8508ac (opens source in a new tab)

      Brexpiprazole label

      Version not recorded · Effective date not recorded

      Elimination Metabolism Based on in vitro metabolism studies of brexpiprazole using recombinant human cytochrome P450 (CYP1A1, 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A4), the metabolism of brexpiprazole was shown to be mainly mediated by CYP3A4 and CYP2D6.
    2. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:993b584c-7fe6-4551-899f-39146c8508ac (opens source in a new tab)

      Brexpiprazole label

      Version not recorded · Effective date not recorded

      Elimination Metabolism Based on in vitro metabolism studies of brexpiprazole using recombinant human cytochrome P450 (CYP1A1, 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A4), the metabolism of brexpiprazole was shown to be mainly mediated by CYP3A4 and CYP2D6.

  10. Projected row 940

    Medicine slug
    brexpiprazole
    Medicine name
    Brexpiprazole
    Enzyme or transporter
    CYP2D6
    Role
    INHIBITOR
    Asserted sentences
    4
    Denied sentences
    0
    Polarity not recorded
    0
    Complete sentence records
    1. ASSERTEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:993b584c-7fe6-4551-899f-39146c8508ac (opens source in a new tab)

      Brexpiprazole label

      Version not recorded · Effective date not recorded

      Based on simulation, a 5.1-fold increase in AUC values at steady-state is expected when extensive metabolizers of CYP2D6 are administered with both strong CYP2D6 and CYP3A4 inhibitors.
    2. ASSERTEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:993b584c-7fe6-4551-899f-39146c8508ac (opens source in a new tab)

      Brexpiprazole label

      Version not recorded · Effective date not recorded

      A 4.8-fold increase in mean AUC values at steady-state is expected in poor metabolizers of CYP2D6 administered with strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )].
    3. ASSERTEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:993b584c-7fe6-4551-899f-39146c8508ac (opens source in a new tab)

      Brexpiprazole label

      Version not recorded · Effective date not recorded

      Based on simulation, a 5.1-fold increase in AUC values at steady-state is expected when extensive metabolizers of CYP2D6 are administered with both strong CYP2D6 and CYP3A4 inhibitors.
    4. ASSERTEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:993b584c-7fe6-4551-899f-39146c8508ac (opens source in a new tab)

      Brexpiprazole label

      Version not recorded · Effective date not recorded

      A 4.8-fold increase in mean AUC values at steady-state is expected in poor metabolizers of CYP2D6 administered with strong CYP3A4 inhibitors [see Drug Interactions ( 7.1 )].

Access

Query or download the projection

View this filtered page as JSONDownload up to 200 filtered CSV rows
GET /api/datasets/enzyme-transporter-negatives?limit=10&offset=930

Allowed query parameters

q
Case-insensitive text search over the public fields named for this dataset.
role
Exact recorded role.Values: INDUCER, INHIBITOR, NOT_RECORDED, SUBSTRATE
counterparty
Exact recorded counterparty spelling.
limit / offset
Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.

Reuse and corrections

Keep the boundary attached

CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.

Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.

Read the correction policy